Joincare Pharmaceutical Group Industry Co.,Ltd.

Equities

600380

CNE000001816

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
11.81 CNY +0.94% Intraday chart for Joincare Pharmaceutical Group Industry Co.,Ltd. +1.03% -4.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Joincare Pharma Says Flu Drug Phase 3 Trial Attains Primary Endpoint MT
Joincare Pharmaceutical Successfully Completes TG-1000 Phase III Study CI
Joincare Pharmaceutical Group's 2023 Profit Falls 4%; Shares Slide 4% MT
Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug MT
Livzon Pharmaceutical Appoints Former Joincare Exec as Vice President MT
Boan Biotechnology, Joincare Sign Exclusive License Deal for Respiratory Disease Treatment MT
Shandong Boan Biotechnology Co., Ltd. Enters into Agreement with Joincare Pharmaceutical Group Industry Co., Ltd CI
Joincare Pharmaceutical, Guangzhou Fermion Technology Get Nod to Trial Analgesic Drug MT
Livzon Pharmaceutical to Continue Getting Services from Joincare Pharmaceutical MT
Joincare Pharma’s 210 Drugs Included in China's Medical Insurance Catalog MT
Joincare Gets Nod to Trial Pain Relief Drug MT
Joincare Pharma Shortlisted For China’s Drug Procurement Program MT
Tranche Update on Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback Plan announced on December 15, 2022. CI
Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback announced on December 15, 2022 has closed with 49,706,643 shares, representing 2.61% for CNY 599.91 million. CI
Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Joincare Pharma Unit Gets Go Signal from China for Phase 3 Trial of Endometriosis Drug MT
Tranche Update on Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback Plan announced on December 15, 2022. CI
Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Livzon Pharmaceutical Gets Nod to Register Blonanserin Tablets MT
Joincare Pharma's Unit Gets Nod for COVID-19 Vaccine Trial MT
Tranche Update on Joincare Pharmaceutical Group Industry Co.,Ltd.'s Equity Buyback Plan announced on December 15, 2022. CI
Joincare Pharma Unit Gets Nod for Anti-Bacterial Drug MT
Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Joincare Pharma Unit Increases Steam, Power Purchase MT
Chart Joincare Pharmaceutical Group Industry Co.,Ltd.
More charts
Joincare Pharmaceutical Group Industry Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals and healthcare products. The Company's products include chemical materials and intermediates, chemical agents, health products, traditional Chinese medicines, diagnostic reagents and equipment. The Company is also engaged in electricity business. The Company distributes its products within domestic market and to overseas markets.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
11.81 CNY
Average target price
14.31 CNY
Spread / Average Target
+21.17%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 600380 Stock
  4. News Joincare Pharmaceutical Group Industry Co.,Ltd.
  5. Joincare Pharmaceutical Industry : Sets Up $15 Million Drug Development JV with Livzon Pharma